Sowa Jan-Peter, Gerken Guido, Canbay Ali
Department of Gastroenterology and Hepatology, University Hospital, University Duisburg-Essen, Essen, Germany.
Dig Dis. 2016;34(4):423-8. doi: 10.1159/000444557. Epub 2016 May 11.
Acute liver failure (ALF) is characterized by a sudden loss of hepatic function due to hepatocyte cell death and dysfunction in previously healthy individuals. The clinical presentation of ALF is associated with coagulopathy (international normalized ratio ≥1.5) and hepatic encephalopathy, although the latter may be less pronounced. Without appropriate and timely intensive care or liver transplantation (LTx), ALF will result in multi-organ failure and death. Various causes may induce ALF, with acetaminophen (APAP) intoxication and acute hepatitis B infection as most common causes in industrialized countries. While conventional terminology discerns acute, acute-on-chronic and acute-on cirrhosis liver failure, some chronic liver diseases (i.e. autoimmune hepatitis (AIH), Wilson's disease) can remain undiagnosed until an initial presentation as ALF.
Upon definite diagnosis of ALF, the underlying cause must be identified, since etiology affects prognosis and clinical management. Individual prognosis should be evaluated with one of various available scoring systems. Most widely used are Model for End-Stage Liver Disease, the King's College Criteria and the Clichy criteria. Other markers, that is, cell death markers, lactate or thyroid status, may improve diagnostic accuracy of classic scores, though routine use of these is not yet established. Etiology-specific treatment under intensive care should be performed, if possible (APAP and amanita intoxication, acute viral hepatitides and AIH). LTx is the only curative option for other causes, unknown reasons of ALF or when etiology-specific therapy fails. In ambiguous cases, that is, suspected drug induced ALF or AIH, co-infection with hepatitis E virus should be tested, as this might be more common than it is currently supposed to be.
Despite major improvements in clinical management of ALF patients, a significant proportion of ALF cases remains without clear identification of the underlying cause or unrecognized multiple causes. In depth analyzes of ambiguous ALF cases is warranted to further improve clinical management.
急性肝衰竭(ALF)的特征是在既往健康的个体中,由于肝细胞死亡和功能障碍导致肝功能突然丧失。ALF的临床表现与凝血病(国际标准化比值≥1.5)和肝性脑病相关,尽管后者可能不太明显。如果没有适当及时的重症监护或肝移植(LTx),ALF将导致多器官功能衰竭和死亡。多种原因可诱发ALF,对乙酰氨基酚(APAP)中毒和急性乙型肝炎感染是工业化国家最常见的病因。虽然传统术语区分急性、慢性加急性和肝硬化急性肝衰竭,但一些慢性肝病(即自身免疫性肝炎(AIH)、威尔逊病)在首次表现为ALF之前可能一直未被诊断出来。
在确诊ALF后,必须确定潜在病因,因为病因会影响预后和临床管理。应使用各种可用的评分系统之一评估个体预后。使用最广泛的是终末期肝病模型、国王学院标准和克利希标准。其他标志物,即细胞死亡标志物、乳酸或甲状腺状态,可能会提高经典评分的诊断准确性,尽管这些标志物的常规使用尚未确立。如有可能,应在重症监护下进行病因特异性治疗(APAP和鹅膏中毒、急性病毒性肝炎和AIH)。LTx是其他病因、ALF原因不明或病因特异性治疗失败时的唯一治愈选择。在不明确的病例中,即疑似药物性ALF或AIH,应检测是否合并戊型肝炎病毒感染,因为这种情况可能比目前认为的更常见。
尽管ALF患者的临床管理有了重大改善,但仍有相当一部分ALF病例的潜在病因未得到明确识别或未被认识到存在多种病因。有必要对不明确的ALF病例进行深入分析,以进一步改善临床管理。